Gyan Barik MAICD’s Post

When we talk about use cases for #GenAI, I think it's fair to say that healthcare could be one of the most important industries. From improving and customizing treatments to the development of lifesaving drugs I'm eager to see what the next 5-10 years of technological advancement brings and how that helps improve health outcomes and quality of life. Current examples of how AI is advancing healthcare and life science today can also be found here: https://lnkd.in/gTN2Z9S6 #IAmIntel https://lnkd.in/gj3RWtcA

🚀 Unlocking the Future of Drug Discovery with Generative AI 🧬 🔍 Dive into the groundbreaking world of #generative AI and its impact on #healthcare, shaping the future of drug discovery processes and revolutionizing patient care! That's the potential of this cutting-edge technology and it’s transforming healthcare and its innovations. Here at #VAST, we're keeping a pulse on these cutting-edge advancements. With our expertise in healthcare services, we're poised to harness the full potential of this game-changing technology 🖥️. We can be your partner in navigating the complexities of healthcare IT. Join us in exploring how generative AI could be the key to designing the next medical breakthrough🧬🔍. What are your thoughts on AI-powered drug discovery? 🌐💊Share your insights in the comments below!💡🚀 . . . To know more connect with us at www.valueaddsofttech.com #generativeAI #healthcareinnovation #healthcare #AIinhealthcare #futureofmedicine #drugdiscovery #healthtechleaders #innovativesolutions #transformativetechnology #VASThealthcare #VAST #Valueadd

Have you ever wished you had a crystal ball to predict clinical trial outcomes? Now, we're one step closer, thanks to AI. Imagine the scene: You're knee-deep in the world of clinical trials. You've seen half of them fall through between Phase II & III. Trillions of dollars and decades of work vanished. Enter the scene: Insilico Medicine, an AI drug discovery company, with its ace - a transformer-based AI tool named inClinico. This isn't your ordinary tool, folks. It's been through a 7-year litmus test, facing the trials and tribulations of clinical trials - and what's come out the other side? A high degree of accuracy in predicting their outcomes. Insilico didn't just create an AI model overnight. This has been a journey that began in 2014. The AI was put through its paces - retrospective, quasi-prospective, and prospective validation. The result? The model demonstrated a stunning 79% accuracy on the outcomes of actual trials. This is far from just an academic exercise. This has profound implications for drug discovery, investors and the whole biotech industry. It's more than an AI tool. It's a SaaS software platform ready to collaborate, evaluate, and predict. #ai #drugdiscovery #clinicaltrials

We are excited to announce publication of a white paper providing a unified vision for Generative Artificial Intelligence (GenAI) in the practice of Medical Affairs. To create this vision, the MAPS organization leveraged the expertise of MAPS Partner Circle companies, many of which are at the forefront of developing AI solutions. We then solicited input from the MAPS Executive Consortium, which is composed of Medical Affairs leaders from across MAPS Industry Partnership Program companies. The result is first-of-its-kind guidance combining perspectives from across industry and solution provider organizations to detail the transformational promise of GenAI technologies -- as well as pinpointing areas of concern. Read the full paper here: https://lnkd.in/gxiHgWcu Special thanks to Peter Piliero and Matt Lewis, who brought immediacy to this initiative that had been percolating but not quite launching since panels on this topic at MAPS Americas and EMEA annual meetings last Spring! And huge thanks to MAPS Partner Circle organizations! Check out our full list of participating companies and filter by solution here: https://lnkd.in/gnUi4PFw (Speaking of, for MAPS Partner Circle companies reading this, you can still submit articles for our nascent Med Affairs GenAI use cases library, which can be seen here: https://lnkd.in/gtVPMzj8) The following companies contributed to this paper: Amedea Pharma , Anju Software, Charles River Associates, Enago Life Sciences, Fishawack Health, Healthcare Consultancy Group - HCG, Huma.AI, ICON plc, Indegene, Inizio, IPG Health, Pharmaspectra, an IQVIA business, Lumanity, MedThink SciCom, OKRA.ai, OM1, Inc., OPEN Health, Oxford PharmaGenesis, Parexel, phactMI, Precision Value & Health, Putnam, PwC, Red Nucleus, Sorcero, Symbiotix, LLC, Syneos Health, The Medical Affairs Company (TMAC), Veeva Systems, Within3, ZS #medicalaffairs #medaffairs #genai #generativeai #pharma #pharmaceuticalindustry

It was really interesting to be part of the group that developed this white paper. So many fascinating discussions around genAI. It's very clear that there is so much potential in this area and I am excited to be exploring it further at OPEN Health as we develop our AI roadmap. OPEN Health #medicalaffairs #genAI #pharma #AIinhealthcare

The team at OKRA.ai, part of Envision Pharma Group, participated in creating a MAPS white paper to provide a unified vision for Generative Artificial Intelligence (GenAI) in the practice of medical affairs. This paper serves as a guide to navigating the integration of artificial intelligence into all facets of medical affairs. 🤖🧬 You can access the full report here https://lnkd.in/gxiHgWcu #EnvisionPharma #medicalaffairs #medaffairs #AI #genai #generativeai #pharma #pharmaceuticalindustry

I just read the white paper delivered by MAPS on how #GenAI is going to transform the way we do #MedicalAffairs. Found it really insightful. This technology is a reality that we need to embrace and help develop rather than confront and try to make fail. It will be used increasingly by Health Care Professionals and Patients so we better start teaching the algorithm to reduce the amount of "hallucination" and incorrect outputs. It also raises a lot of questions regarding compliance, copyright and confidentiality. Please, don't miss the final chapter which is the same question that the white paper is trying to respond, BUT responded by ChatGPT. Not bad if you ask me! (kind of spooky...)

Gen AI is quickly entering into every aspect of healthcare from backoffice to patient engagement and drug discovery. Recently released Gen AI Healthcare Partnerships and Investment Update Aug 2023. A summary of recent partnerships, investments and applications for this new technology. https://lnkd.in/ga6RkP58 #genai #healthcareinnovation #ai #openai #bard #chatgpt #healthcarevc #healthcareai #aiinnovation #LLM

Gen AI has taken life sciences by storm, but what can really help you in your business, and what is hype? KPMG is at the heart of squashing the hype and focusing on serving our clients new, practical offerings. Check out our work in the value chain across discovery research, preclinical development, clinical trials and commercialization and our latest impact paper on Gen AI’s impact on patient care 🧬 #KPMGPrecisionMedicine #lifesciences #GenAI #KPMGHCLS

Generative AI is a new and rapidly emerging form of artificial intelligence that has the potential to revolutionize precision medicine by improving diagnosis, treatment, and drug discovery. KPMG unveils evolving trends and impact of gen AI on patient care. #kpmg @precisionmedicine @genAI #lifesciences